(CL) Colgate-Palmolive - Overview
Stock: Toothpaste, Soap, Shampoo, Detergent, Pet-Food
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.98% |
| Yield on Cost 5y | 2.98% |
| Yield CAGR 5y | 3.57% |
| Payout Consistency | 99.6% |
| Payout Ratio | 57.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.6% |
| Relative Tail Risk | -2.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.01 |
| Alpha | -1.23 |
| Character TTM | |
|---|---|
| Beta | 0.034 |
| Beta Downside | 0.003 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.05% |
| CAGR/Max DD | 0.32 |
Description: CL Colgate-Palmolive January 27, 2026
Colgate-Palmolive (NYSE: CL) is a diversified consumer-goods company that sells oral, personal, and home-care products worldwide, plus pet-nutrition items under the Hill’s Science Diet and Prescription Diet brands. Its two operating segments are (1) Oral, Personal & Home Care, which includes a portfolio of more than 30 household names such as Colgate, Palmolive, Tom’s of Maine, Irish Spring and Ajax, and (2) Pet Nutrition, which distributes therapeutic and everyday pet foods through pet-supply retailers, veterinarians and e-commerce channels.
In FY 2023 the company generated $17.4 billion in revenue, up 3 % YoY, with an adjusted EPS of $2.73 and a dividend yield of roughly 2.4 %. The Pet Nutrition segment posted a 6 % revenue increase, driven by higher demand for premium therapeutic diets, while the Oral, Personal & Home Care segment remained flat, reflecting modest pricing pressure from inflation. The firm’s operating margin stayed near 15 % and cash flow from operations exceeded $3 billion, supporting its $1.5 billion share-repurchase program.
Key drivers for the sector include persistent inflation that squeezes discretionary spend but leaves essential oral-care and pet-nutrition demand relatively resilient, accelerating e-commerce penetration (online sales now represent ~22 % of total revenue), and a secular trend of rising pet-ownership spending, which historically outpaces overall consumer-goods growth by 4-5 % annually. A slowdown in global economic growth or a sharp increase in raw-material costs could pressure margins, while continued brand-strength and innovation in “premium-care” categories may offset those risks.
For a deeper, data-driven valuation, you may find ValueRay’s analytical toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.91b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA -0.61 > 1.0 |
| NWC/Revenue: -2.27% < 20% (prev 1.20%; Δ -3.47% < -1%) |
| CFO/TA 0.23 > 3% & CFO 4.01b > Net Income 2.91b |
| Net Debt (7.14b) to EBITDA (4.81b): 1.48 < 3 |
| Current Ratio: 0.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (810.2m) vs 12m ago -1.50% < -2% |
| Gross Margin: 60.15% > 18% (prev 0.60%; Δ 5955 % > 0.5%) |
| Asset Turnover: 117.2% > 50% (prev 119.9%; Δ -2.64% > 0%) |
| Interest Coverage Ratio: 15.57 > 6 (EBITDA TTM 4.81b / Interest Expense TTM 270.0m) |
Altman Z'' 8.10
| A: -0.03 (Total Current Assets 6.04b - Total Current Liabilities 6.50b) / Total Assets 17.51b |
| B: 1.54 (Retained Earnings 27.05b / Total Assets 17.51b) |
| C: 0.25 (EBIT TTM 4.20b / Avg Total Assets 17.14b) |
| D: 1.51 (Book Value of Equity 24.63b / Total Liabilities 16.27b) |
| Altman-Z'' Score: 8.10 = AAA |
Beneish M -3.04
| DSRI: 1.06 (Receivables 1.81b/1.71b, Revenue 20.10b/20.11b) |
| GMI: 1.00 (GM 60.15% / 60.29%) |
| AQI: 1.01 (AQ_t 0.39 / AQ_t-1 0.39) |
| SGI: 1.00 (Revenue 20.10b / 20.11b) |
| TATA: -0.06 (NI 2.91b - CFO 4.01b) / TA 17.51b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of CL shares?
Over the past week, the price has changed by +4.19%, over one month by +14.25%, over three months by +18.73% and over the past year by +1.79%.
Is CL a buy, sell or hold?
- StrongBuy: 7
- Buy: 6
- Hold: 7
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the CL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88.9 | -1.6% |
| Analysts Target Price | 88.9 | -1.6% |
| ValueRay Target Price | 96.9 | 7.4% |
CL Fundamental Data Overview January 31, 2026
P/E Forward = 22.0751
P/S = 3.428
P/B = 80.2675
P/EG = 3.2917
Revenue TTM = 20.10b USD
EBIT TTM = 4.20b USD
EBITDA TTM = 4.81b USD
Long Term Debt = 7.31b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, last quarter)
Debt = 8.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.14b USD (from netDebt column, last quarter)
Enterprise Value = 76.03b USD (68.89b + Debt 8.42b - CCE 1.28b)
Interest Coverage Ratio = 15.57 (Ebit TTM 4.20b / Interest Expense TTM 270.0m)
EV/FCF = 22.08x (Enterprise Value 76.03b / FCF TTM 3.44b)
FCF Yield = 4.53% (FCF TTM 3.44b / Enterprise Value 76.03b)
FCF Margin = 17.13% (FCF TTM 3.44b / Revenue TTM 20.10b)
Net Margin = 14.47% (Net Income TTM 2.91b / Revenue TTM 20.10b)
Gross Margin = 60.15% ((Revenue TTM 20.10b - Cost of Revenue TTM 8.01b) / Revenue TTM)
Gross Margin QoQ = 59.42% (prev 60.06%)
Tobins Q-Ratio = 4.34 (Enterprise Value 76.03b / Total Assets 17.51b)
Interest Expense / Debt = 0.80% (Interest Expense 67.0m / Debt 8.42b)
Taxrate = 22.78% (226.0m / 992.0m)
NOPAT = 3.25b (EBIT 4.20b * (1 - 22.78%))
Current Ratio = 0.93 (Total Current Assets 6.04b / Total Current Liabilities 6.50b)
Debt / Equity = 9.84 (Debt 8.42b / totalStockholderEquity, last quarter 856.0m)
Debt / EBITDA = 1.48 (Net Debt 7.14b / EBITDA 4.81b)
Debt / FCF = 2.07 (Net Debt 7.14b / FCF TTM 3.44b)
Total Stockholder Equity = 533.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.96% (Net Income 2.91b / Total Assets 17.51b)
RoE = 545.1% (Net Income TTM 2.91b / Total Stockholder Equity 533.2m)
RoCE = 53.63% (EBIT 4.20b / Capital Employed (Equity 533.2m + L.T.Debt 7.31b))
RoIC = 36.55% (NOPAT 3.25b / Invested Capital 8.88b)
WACC = 5.45% (E(68.89b)/V(77.31b) * Re(6.04%) + D(8.42b)/V(77.31b) * Rd(0.80%) * (1-Tc(0.23)))
Discount Rate = 6.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.91%
[DCF Debug] Terminal Value 87.29% ; FCFF base≈3.43b ; Y1≈3.79b ; Y5≈4.92b
Fair Price DCF = 171.3 (EV 145.22b - Net Debt 7.14b = Equity 138.08b / Shares 806.1m; r=5.90% [WACC]; 5y FCF grow 12.34% → 2.90% )
EPS Correlation: -15.00 | EPS CAGR: -45.30% | SUE: -4.0 | # QB: 0
Revenue Correlation: 91.48 | Revenue CAGR: 4.16% | SUE: 0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.94 | Chg30d=-0.001 | Revisions Net=-1 | Analysts=13
EPS next Year (2026-12-31): EPS=3.84 | Chg30d=+0.004 | Revisions Net=+1 | Growth EPS=+5.2% | Growth Revenue=+3.6%